智通财经记者 | 黄华 历史资料显示，海薇和姣兰的首次获批时间分别是2013年9月、2016年9月。这也意味着，入门级别的玻 尿酸产品在国内的红利期远没能撑到10年。 智通财经此前报道，昊海生科的医美业务此前就已出现增长压力。2021年-2024年，该公司医疗美容与 创面护理产品收入为4.6亿元、7.5亿元、10.6亿元、12亿元；其中，玻尿酸创收2.4亿元、3亿元、6亿 元、7.4亿元。 智通财经编辑 | 谢欣 近日，昊海生科发布2025年半年度报告。数据显示，公司于期内营利双降，但降幅一般——企业实现营 收13.04亿元，同比下降7.12%；实现归母净利润、扣非净利润2.11亿元、2.04亿元，同比下降10.29%、 11.35%。 对于昊海生科的业绩情况，智通财经记者向公司发送了采访提纲。截至发稿时，未获得回复。 截至8月25日收盘，昊海生科A股报57.62元./股，涨0.24%，最新总市值134亿元；H股报29.66港元/股， 涨1.16%，最新总市值69亿港元。 昊海生科是国内医疗器械领域的知名公司，主要布局医美、眼科和骨科。过去几年，前述业务代表了高 毛利。企业官网显示，昊海生科的主要产品包括人工 ...

Core Viewpoint - The recent investigation of Jiang Wei, a major shareholder of Haohai Biological Technology, by the China Securities Regulatory Commission for suspected insider trading is not expected to significantly impact the company's operations or stock performance [1][2]. Company Overview - Haohai Biological Technology is recognized for its "medical aesthetics + ophthalmology" business model, with a focus on high-margin products such as artificial lenses and medical-grade hyaluronic acid [2][3]. - The company is the first biopharmaceutical firm listed on both the Hong Kong Stock Exchange and the Shanghai Stock Exchange's Sci-Tech Innovation Board [2]. Financial Performance - Revenue has shown consistent growth from 1.3 billion yuan in 2020 to 2.6 billion yuan in 2024, while net profit increased from 200 million yuan to 400 million yuan during the same period, despite a significant drop in 2022 [2][3]. - In 2024, the company reported revenue of 2.698 billion yuan, a year-on-year increase of 1.64%, and a net profit of 420 million yuan, up 1.04% [3]. Market Challenges - The medical aesthetics and ophthalmology sectors are facing increased competition and price reductions due to national procurement policies, leading to stagnation in revenue growth for 2024 [3]. - The medical aesthetics segment has shown signs of growth fatigue, with revenues from medical beauty and wound care products increasing from 460 million yuan in 2021 to 1.2 billion yuan in 2024, but growth rates are declining [3]. Product Development - In July 2024, Haohai Biological Technology received approval for its fourth-generation hyaluronic acid product, Hai Mei Yue Bai, aimed at treating moderate to severe nasolabial folds, positioning it as a potential growth driver in the high-end medical aesthetics market [4]. - The product is priced at 13,800 yuan for 1ml and 19,800 yuan for 2ml, indicating a premium positioning [4]. Recent Performance - In the first quarter of 2024, the company experienced a decline in both revenue and net profit, with revenue at 619 million yuan, down 4.25%, and net profit at approximately 90.31 million yuan, down 7.41% [4].

Group 1 - The company, Opcon Vision (300595), has received a medical device registration certificate from the National Medical Products Administration for its new product, "Orthokeratology Rigid Gas Permeable Contact Lens" [1] - The product is designed for temporary correction of myopia for users with myopia degrees between -0.50D and -4.00D and astigmatism degrees within 1.50D [1] - The product is non-sterile and requires cleaning and disinfection before use, with a recommended replacement cycle of one year and a shelf life of five years [1]